Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) traded up 5.3% on Wednesday . The company traded as high as $30.68 and last traded at $30.92. 49,829 shares were traded during trading, a decline of 94% from the average session volume of 816,290 shares. The stock had previously closed at $29.37.
Wall Street Analysts Forecast Growth
A number of research analysts have weighed in on the company. The Goldman Sachs Group assumed coverage on Crinetics Pharmaceuticals in a report on Thursday. They set a "neutral" rating and a $36.00 target price for the company. Stifel Nicolaus assumed coverage on Crinetics Pharmaceuticals in a report on Tuesday, March 25th. They set a "buy" rating and a $60.00 target price for the company. Finally, HC Wainwright reaffirmed a "buy" rating and set a $81.00 target price on shares of Crinetics Pharmaceuticals in a report on Friday, June 27th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $69.50.
Read Our Latest Analysis on CRNX
Crinetics Pharmaceuticals Stock Performance
The stock has a market cap of $3.00 billion, a P/E ratio of -8.37 and a beta of 0.25. The stock has a 50-day moving average price of $31.00 and a 200-day moving average price of $34.67.
Crinetics Pharmaceuticals (NASDAQ:CRNX - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.99) by ($0.05). The firm had revenue of $0.36 million during the quarter, compared to analysts' expectations of $0.10 million. The company's revenue was down 43.6% on a year-over-year basis. During the same period in the previous year, the business posted ($0.93) EPS. Sell-side analysts forecast that Crinetics Pharmaceuticals, Inc. will post -3.73 earnings per share for the current fiscal year.
Insider Activity
In other news, insider Stephen F. Betz sold 97,483 shares of Crinetics Pharmaceuticals stock in a transaction dated Thursday, June 12th. The stock was sold at an average price of $32.23, for a total transaction of $3,141,877.09. Following the completion of the sale, the insider owned 99,713 shares in the company, valued at approximately $3,213,749.99. This trade represents a 49.43% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 4.60% of the company's stock.
Institutional Trading of Crinetics Pharmaceuticals
Hedge funds have recently bought and sold shares of the company. KLP Kapitalforvaltning AS bought a new stake in Crinetics Pharmaceuticals in the 4th quarter worth approximately $818,000. Alliancebernstein L.P. lifted its position in Crinetics Pharmaceuticals by 9.9% in the 4th quarter. Alliancebernstein L.P. now owns 101,720 shares of the company's stock worth $5,201,000 after buying an additional 9,190 shares during the last quarter. Invesco Ltd. lifted its position in Crinetics Pharmaceuticals by 16.8% in the 4th quarter. Invesco Ltd. now owns 298,254 shares of the company's stock worth $15,250,000 after buying an additional 42,954 shares during the last quarter. GAMMA Investing LLC lifted its position in Crinetics Pharmaceuticals by 6,291.5% in the 1st quarter. GAMMA Investing LLC now owns 6,775 shares of the company's stock worth $227,000 after buying an additional 6,669 shares during the last quarter. Finally, Wells Fargo & Company MN lifted its position in Crinetics Pharmaceuticals by 18.9% in the 4th quarter. Wells Fargo & Company MN now owns 100,916 shares of the company's stock worth $5,160,000 after buying an additional 16,025 shares during the last quarter. Institutional investors own 98.51% of the company's stock.
Crinetics Pharmaceuticals Company Profile
(
Get Free Report)
Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.
Recommended Stories
Before you consider Crinetics Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Crinetics Pharmaceuticals wasn't on the list.
While Crinetics Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.